Retinal Disease Research & Development
Developing Sustained-Release Drug Delivery Platforms for Retinal Diseases
Sign Up For Updates
Retinal Diseases Vary Widely, Can Affect Any Part of the Retina, and Are Leading Causes of Blindness Worldwide
The thin layer of tissue on the inside back wall of the eye, the retina, contains millions of cells that receive, organise and send visual information through the optic nerve to the brain, enabling vision. AMD and diabetic retinopathies are the most common degenerative retinal diseases. Market Scope estimates that approximately 28 million people in the United States suffer from some type of retinal disease or condition, including approximately 17 million people with AMD.
Retinal Disease Programs Currently in Development
Retinal Disease Research Area
Triamcinolone Acetonide SR (RVO & DME)
Developing formulations to release triamcinolone acetonide for up to 6 months.
Retinal Disease Research Area
Multi-Kinase Inhibitor SR (Wet AMD, RVO & DME)
Developing a multi-kinase inhibitor small molecule sustained-release delivery system.
Retinal Disease Research Area
Anti-VEGF SR (Wet, RVO & DME)
Developing sustained release, hydrogel-based, erodible implant with protein stabilisation technology.
Sign up to receive the latest information on our retinal disease programs, including research findings and more
Stay Connected
"*" indicates required fields